Previous 10 | Next 10 |
2023-04-06 08:23:15 ET Lumentum Holdings ( LITE ) -14% on lowering Q3 expectations. Scilex Holding Company ( SCLX ) -13% a nnounces p ostponement of annual meeting of stockholders. AMC Entertainment Holdings ( APE ) -12% as court rules against c...
InflaRx N.V. (NASDAQ: IFRX) is one today's most active stocks by volume. So far today, approximately 60.87M shares of InflaRx N.V. have been exchanged, as compared to an average 30-day volume of 620.81k shares. InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops in...
2023-04-05 11:57:18 ET Shares of InflaRx (NASDAQ: IFRX) were up 48% an hour after the market opened on Wednesday on news the company's COVID-19 therapy was receiving an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). The German clinical-stage biotech...
2023-04-05 10:07:20 ET Gainers: Liminal BioSciences ( LMNL ) +81% . InflaRx ( IFRX ) +51% . 180 Life Sciences ( ATNF ) +26% . YS Biopharma ( YS ) +22% . Immunic ( IMUX ) +21% . Losers: Bullfrog AI ( BFRG ) -15% ....
2023-04-05 08:13:52 ET Liminal BioSciences ( LMNL ) +89% c onfirms receipt of unsolicited non-binding transaction proposal. 180 Life Sciences ( ATNF ) +33% . Immunic ( IMUX ) +23% as imu-838 shows promise in ulcerative colitis trial. Freig...
2023-04-04 15:13:30 ET InflaRx ( NASDAQ: IFRX ) stock has surged 60% in Tuesday afternoon trading after the US FDA authorized the company's COVID-19 treatment Gohibic (vilobelimab). The Emergency Use Authorization was based on results from a phase 3 trial that showed a...
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune response FDA granted EUA based on Phase III clinical trial results showing a significant relative reduction in 28-day all-cause mortality of...
2023-04-03 08:55:13 ET Summary In December of 2022 I introduced a number of stocks which I was adding to my "Tax Loss Selling Basket". In this article I summarize the logic and criteria for the basket. I then tally up the results including calculating overall returns and looki...
2023-03-22 08:49:45 ET InflaRx press release ( NASDAQ: IFRX ): FY GAAP EPS of -€0.67. As of December 31, 2022, InflaRx’s total funds available amounted to approximately €83.7 million, comprised of €16.3 million of cash and cash equiv...
Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol submitted; first patient expected around mid-2023 Fast Track and Orphan Drug desig...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...